ALC vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Alcon Inc. (ALC) exhibits a weak Piotroski F-Score of 4/9, indicating marginal financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth and strong gross margins, earnings are contracting year-over-year, and the stock trades at a high valuation (P/E 38.60 vs. sector average 212.00) with a weak technical trend. Analysts recommend a 'buy' with a $91.80 target, implying 14% upside, but this is at odds with deteriorating profitability and low insider sentiment. The Graham Number of $45.87 suggests significant overvaluation, though sector dynamics and growth expectations may justify some premium.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ALC vs MRK: Head-to-Head Comparison
This page compares Alcon Inc. (ALC) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.